Companies
Moderna
BiotechnologyCambridge, MassachusettsMRNAAbout 4,700 employees
More about Moderna
Biotechnology company that develops and sells mRNA vaccines and medicines, including COVID-19 vaccines
Revenue
$1.9B
Fiscal 2025, down 40%
Employees
About 4,700
As of December 2025
Stock
MRNA
Nasdaq
Headquarters
Cambridge, Massachusetts
CEO
Stéphane Bancel
BrandsSpikevax, mNEXSPIKE, mRESVIA
Current strategyTargeting up to 10% revenue growth in 2026 through mNEXSPIKE and international partnerships while continuing to cut operating expenses
Recent workforce changesAbout 10% of the global workforce cut, announced July 2025, aiming for fewer than 5,000 employees by end of 2025
CompetitorsPfizer, BioNTech, Novavax
Checked October 11, 2026 · Sources: biospace.com, cp24.com, tickerleague.com
No source-backed updates for Moderna yet. They appear here when a public report or filing covers the company.
No one has posted about Moderna yet. Be the first to post ›
Follow Moderna in a feed reader, no account needed: RSS feed